Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boulder, CO, US. The stock last traded at $44.26, down 0.11% on the session, giving a market capitalisation of $4.76B. On trailing twelve-month figures it carries a trailing P/E of -23.92, a net margin of 0.0%. Its beta of 0.28 implies it has historically moved less than the broad market.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Edgewise Therapeutics, Inc. is most often compared with the following Healthcare names: